0.41 USD
↘ 0.03 (6.16%)AT CLOSE (03:59 PM EST)
Outlook Therapeutics, Inc. Common Stock
OTLKNASDAQ • USD
0.41
↗ 0.00 (0.00%)
POST MARKET (AS OF 07:59 PM EST)
Post Market
AS OF 07:59 PM EST
0.41
↗ 0.00 (0.00%)
Market: CLOSED
Outlook Therapeutics, Inc. Common Stock (OTLK) is currently trading at $0.41. Both sides of the analysis point lower: technicals flash "Strong Sell" and fundamentals confirm with a "Strong Sell" reading. This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 2/9, exceptional Return on Equity (460.2%), a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment.
Technical & fundamental data as of Nov 13, 2026.
Open?$0.46
High?$0.46
Low?$0.41
Prev. Close?$0.44
Volume?3.0M
Avg. Volume?3.5M
VWAP?$0.42
Rel. Volume?0.87x
Bid / Ask
Bid?$0.41 × 1.5K
Ask?$0.41 × 200
Spread?$0.00
Midpoint?$0.41
Valuation & Ratios
Market Cap?99.8M
Shares Out?243.4M
Float?213.0M
Float %?87.5%
P/E Ratio?N/A
P/B Ratio?-9.60
EPS?-$0.20
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
Employees
17
Market Cap
107.1M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
Listed
2016-05-13
Address
111 S. WOOD AVENUE
ISELIN, NJ 08830
Phone: (609) 619-3990
ISELIN, NJ 08830
Phone: (609) 619-3990
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →Fundamental OutlookStrong Sell
Strong SellNeutralStrong Buy
F-Score?12
Z-Score?0
Momentum?29
Short Sent.?14
Piotroski F-Score?2/9Weak
Altman Z-Score?-38.43Distress
Confidence?65%Moderate
Short InterestVery High
Short % of Float?16.69%High
Short Interest?35.5M
Days to Cover?10.1
Free Float213.0M
Avg Daily Volume3.5M
Settlement Date2026-10-30
Financial Health
Current Ratio?0.81Weak
Quick Ratio?0.63Weak
Cash Ratio?0.39Low
Debt/Equity?-1.75Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score100/100
P/E?N/A▾
P/B?-9.60CHEAP▾
S&P97
P/S?-93.14CHEAP▾
S&P97
P/FCF?N/A▾
EV/EBITDA?-2.8CHEAP▾
S&P97
EV/Sales?-99.65CHEAP▾
S&P97
Returns & Efficiency
ROE?460.2%STRONG▾
Peers50
S&P97
ROA?-182.7%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-56154885
Enterprise Value?$106.8M
Fundamentals ratios updated end of day